Gerosynth launches Mytulin EQ for equine recovery and immune support: full analysis

Gerosynth Labs is entering the equine supplement market with Mytulin EQ, a newly launched nutritional product positioned around immune support, cellular vitality, and performance recovery in horses. The company announced the product in November 2025 through its Mytosynth Nutraceuticals subsidiary, with distribution through its direct-to-consumer site and pricing listed at $280 for a 64-ounce pouch, or $540 for a three-pack, with an introductory discount at launch. (prnewswire.com)

The launch fits a broader pattern in equine health, where companies increasingly frame supplements around cellular function, inflammation, recovery, and longevity rather than around traditional vitamin-mineral support alone. In Mytulin EQ’s case, Gerosynth says the product was developed through proprietary phytochemical research and is based on wild-harvested chaga mushrooms sourced from Alaska’s Arctic Circle. The company’s messaging emphasizes musculoskeletal strength, gastrointestinal balance, and mitochondrial support, but the public-facing announcement does not point to published equine trials, peer-reviewed efficacy data, or a detailed ingredient dossier beyond the chaga-based origin story. (prnewswire.com)

That matters because the regulatory framework for animal supplements is often misunderstood by clients and sometimes by manufacturers. FDA states that DSHEA, the law that created the human “dietary supplement” category, does not apply to animal food. Under FDA’s framework, products marketed for animals are generally treated as either food or new animal drugs depending on intended use and claims. FDA also notes that animal food products must avoid false or misleading labeling and may be considered adulterated or misbranded if they don’t meet legal requirements. (fda.gov)

Gerosynth itself appears to be positioning across both nutraceutical and regulated therapeutic lanes. One month after the Mytulin EQ announcement, the company said FDA’s Center for Veterinary Medicine had accepted multiple Investigational New Animal Drug files for oncology candidates in equine, feline, and canine indications, each with MUMS designation, according to a separate company press release. That doesn’t speak directly to Mytulin EQ’s efficacy, but it does suggest the company wants to be seen not just as a supplement marketer, but as a biotech developer building a larger animal-health platform. (prnewswire.com)

As for outside reaction, the launch coverage available so far is limited and largely reproduces company language. The Horse published the announcement as an edited press release, and broader pickup appears to have been minimal beyond trade aggregation. The only attributed veterinary endorsement in the launch materials comes from Kendall Willson, DVM, MRCVS, who said the formulation gives veterinarians and trainers “a valuable new tool,” but that statement appears within company-issued promotional copy rather than an independent review. (thehorse.com)

Why it matters: For veterinary professionals, Mytulin EQ is less a breakthrough story than a signal of where the equine supplement market is heading. Products framed around mitochondrial health, immune resilience, and recovery are likely to resonate with performance-horse clients, especially when they’re paired with biotech branding and premium pricing. But unless companies publish stronger equine-specific evidence, veterinarians may be left managing expectations, explaining the difference between structure/function-style marketing and demonstrated clinical benefit, and helping pet parents understand that “natural” does not equal proven. FDA’s framework also means intended-use claims can have regulatory implications if a product starts to look more like a drug than a feed or food product. (fda.gov)

There’s also a practical client-communication issue here. When a supplement is marketed for performance recovery, immune support, GI balance, and longevity all at once, veterinarians may need to ask basic but important questions: What exactly is in it, at what dose, for which horses, and with what evidence? In equine practice, those questions matter not only for clinical decision-making, but also for budget discussions, competition considerations, and avoiding substitution of supplements for indicated diagnostics or treatment. The public launch materials answer only part of that picture. (prnewswire.com)

What to watch: The next meaningful development will be whether Gerosynth releases equine safety or efficacy data, expands distribution into veterinary channels, or sharpens its claims in ways that draw more regulatory or industry scrutiny. Until then, Mytulin EQ looks like an ambitious premium supplement launch backed by a company with broader animal-health aspirations, but not yet by much publicly available clinical detail. (prnewswire.com)